BPMC - Blueprint Medicines Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
BPMC price evolution
BPMC
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.96 | $81.52 | $65.67 | $81.88 |
| Short term investments | $534.58 | $639.36 | $657.01 | $647.11 |
| Net receivables | $60.05 | $43.18 | $41.25 | $38.27 |
| Inventory | $30.94 | $21.22 | $16.46 | $17.02 |
| Total current assets | $776.6 | $808.39 | $808.17 | $811.34 |
| Long term investments | $115.49 | $84.32 | $142.03 | $141.72 |
| Property, plant & equipment | $113.17 | $115.65 | $115.84 | $114.49 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $261.87 | $240.86 | $297.13 | $295.11 |
| Total investments | $650.07 | $723.67 | $799.04 | $788.83 |
| Total assets | $1038.47 | $1049.25 | $1105.3 | $1106.44 |
| Current liabilities | ||||
| Accounts payable | $4.93 | $4.71 | $6.96 | $6.98 |
| Deferred revenue | $11.89 | $5.6 | $8.01 | $8.33 |
| Short long term debt | $42.42 | $42.21 | $41.84 | $29.15 |
| Total current liabilities | $206.6 | $214.92 | $197.38 | $169.03 |
| Long term debt | $287.69 | $290.29 | $292.19 | $209.19 |
| Total noncurrent liabilities | $521.18 | $703.72 | $705.3 | $626.29 |
| Total debt | $330.11 | $332.5 | $334.03 | $238.34 |
| Total liabilities | $727.79 | $918.64 | $902.69 | $795.32 |
| Shareholders' equity | ||||
| Retained earnings | -$2250.81 | -$2339.94 | -$2229.03 | -$2095.31 |
| Other shareholder equity | -$3.85 | -$3.5 | -$2.68 | -$4.22 |
| Total shareholder equity | $310.69 | $130.61 | $202.61 | $311.13 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.52 | $124.9 | $215.12 | $689.8 |
| Short term investments | $639.36 | $825.28 | $267.17 | $187.21 |
| Net receivables | $43.18 | $36.94 | $37.03 | $25.31 |
| Inventory | $21.22 | $29.7 | $21.82 | $8.58 |
| Total current assets | $808.39 | $1046.65 | $554.02 | $927.76 |
| Long term investments | $84.32 | $161.27 | $557.53 | $677.87 |
| Property, plant & equipment | $115.65 | $115.2 | $120.86 | $101.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $240.86 | $303.25 | $698.2 | $790.63 |
| Total investments | $723.67 | $986.55 | $824.7 | $865.09 |
| Total assets | $1049.25 | $1349.9 | $1252.22 | $1718.39 |
| Current liabilities | ||||
| Accounts payable | $4.71 | $2.73 | $8.33 | $4.37 |
| Deferred revenue | $5.6 | $18.29 | $36.58 | $41.16 |
| Short long term debt | $42.21 | $27.43 | $8.09 | $7.93 |
| Total current liabilities | $214.92 | $183.23 | $149.76 | $130.8 |
| Long term debt | $290.29 | $122.23 | $103.31 | $81.67 |
| Total noncurrent liabilities | $703.72 | $651.99 | $131.72 | $117.5 |
| Total debt | $332.5 | $242.45 | $111.41 | $89.6 |
| Total liabilities | $918.64 | $835.23 | $281.49 | $248.31 |
| Shareholders' equity | ||||
| Retained earnings | -$2339.94 | -$1832.96 | -$1275.44 | -$631.36 |
| Other shareholder equity | -$3.5 | -$10.44 | -$4.13 | -$5.21 |
| Total shareholder equity | $130.61 | $514.68 | $970.74 | $1470.09 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $96.12 | $71.96 | $56.57 | $57.57 |
| Cost of revenue | $3.19 | $0.21 | $4.55 | $3.56 |
| Gross Profit | $92.92 | $71.74 | $52.01 | $54.01 |
| Operating activities | ||||
| Research & development | $88.19 | $97.54 | $110.25 | $110.06 |
| Selling, general & administrative | $83.56 | $79.31 | $70.74 | $71.93 |
| Total operating expenses | $171.75 | $176.85 | $180.99 | $181.99 |
| Operating income | -$78.82 | -$105.11 | -$128.98 | -$127.98 |
| Income from continuing operations | ||||
| EBIT | $95.21 | -$105.69 | -$129.71 | -$128.61 |
| Income tax expense | $0.18 | $0.06 | $0.2 | $0.19 |
| Interest expense | $5.89 | $5.17 | $3.81 | $4 |
| Net income | ||||
| Net income | $89.14 | -$110.92 | -$133.71 | -$132.79 |
| Income (for common shares) | $89.14 | -$110.92 | -$133.71 | -$132.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $249.38 | $204.04 | $180.08 | $793.74 |
| Cost of revenue | $12.8 | $26.76 | $25.73 | $0.42 |
| Gross Profit | $236.58 | $177.28 | $154.34 | $793.31 |
| Operating activities | ||||
| Research & development | $427.72 | $477.42 | $601.03 | $326.86 |
| Selling, general & administrative | $295.14 | $237.37 | $195.29 | $157.74 |
| Total operating expenses | $722.86 | $714.79 | $796.33 | $484.6 |
| Operating income | -$486.28 | -$537.52 | -$641.98 | $308.71 |
| Income from continuing operations | ||||
| EBIT | -$487.22 | -$535.51 | -$643.47 | $308.34 |
| Income tax expense | $0.97 | $5.24 | $3 | $1.06 |
| Interest expense | $18.79 | $16.77 | -$2.39 | -$6.6 |
| Net income | ||||
| Net income | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| Income (for common shares) | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $89.14 | -$110.92 | -$133.71 | -$132.79 |
| Operating activities | ||||
| Depreciation | $7.21 | $3.88 | $5.17 | $5.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $24.23 | $22.59 | $23.07 | $23.82 |
| Total cash flows from operations | -$101.51 | -$78.93 | -$104.48 | -$130.47 |
| Investing activities | ||||
| Capital expenditures | -$1.1 | -$4.67 | -$6.25 | -$2.55 |
| Investments | $78.23 | $83.44 | -$3.33 | $34.62 |
| Total cash flows from investing | $77.13 | $78.77 | -$9.59 | $32.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $67.33 | $15.61 | $0.43 | $5.3 |
| Net borrowings | -$0.37 | -$0.04 | $97.97 | |
| Total cash flows from financing | $66.96 | $15.53 | $98.4 | $5.3 |
| Effect of exchange rate | -$0.14 | $0.49 | -$0.54 | $0.06 |
| Change in cash and equivalents | $42.58 | $15.37 | -$15.67 | -$93.11 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| Operating activities | ||||
| Depreciation | $20.77 | $20.1 | $12.79 | $12.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $92.67 | $98.97 | $91.63 | $75.53 |
| Total cash flows from operations | -$436.85 | -$502.28 | -$298.65 | $387.04 |
| Investing activities | ||||
| Capital expenditures | -$16.06 | -$8.92 | -$3.09 | -$3.16 |
| Investments | $290.1 | -$140.33 | $35.38 | -$431.09 |
| Total cash flows from investing | $274.04 | -$149.54 | -$225.86 | -$434.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.34 | $8.2 | $50.72 | $617.76 |
| Net borrowings | $97.93 | $137.79 | ||
| Total cash flows from financing | $119.22 | $561.81 | $50.72 | $617.76 |
| Effect of exchange rate | $0.2 | -$0.21 | -$0.89 | -$0.34 |
| Change in cash and equivalents | -$43.58 | -$90.01 | -$473.8 | $570.54 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $282.21M |
|---|---|
| EBITDA | -$246.69M |
| EBIT | -$268.79M |
| Net Income | -$288.29M |
| Revenue Q/Q | 51.87% |
| Revenue Y/Y | 37.94% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -26.82% |
| ROE | -120.74% |
| Debt/Equity | 7.03 |
|---|---|
| Net debt/EBITDA | -2.45 |
| Current ratio | 3.76 |
| Quick ratio | 3.61 |